Analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Rating) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.
Separately, Maxim Group cut Titan Pharmaceuticals to a “hold” rating in a research note on Thursday, May 26th.
TTNP opened at $0.58 on Wednesday. The stock’s 50 day simple moving average is $0.57 and its 200 day simple moving average is $0.88. Titan Pharmaceuticals has a 1 year low of $0.35 and a 1 year high of $3.10.
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union.
- Get a free copy of the StockNews.com research report on Titan Pharmaceuticals (TTNP)
- Are These Cheap Copper Stocks Right For Your Portfolio?
- Zai Lab Stock Has Fallen to Value Levels
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.